Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures - Worldwide, 1997-2000

JAMA

Volumn 285, Issue 4, 2001, Pages 402-403

  Boxwell, D ^a   Haverkos, H ^b,c   Kukich, S ^b,c   Struble, K ^b,c   Jolson, D H ^b,c  

^a Office of Post Marketing Drug Risk Assessment   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; CHEMOPROPHYLAXIS; CHILD; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; NEEDLESTICK INJURY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RHABDOMYOLYSIS; SHORT SURVEY; SKIN MANIFESTATION; UNITED STATES; VIRUS TRANSMISSION; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; LIVER FAILURE; MIDDLE AGED; TOXIC HEPATITIS;

ADULT; ANTI-HIV AGENTS; DRUG ERUPTIONS; FEMALE; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; LAMIVUDINE; LIVER FAILURE; MALE; MIDDLE AGED; NEVIRAPINE; OCCUPATIONAL EXPOSURE; REVERSE TRANSCRIPTASE INHIBITORS; RHABDOMYOLYSIS; ZIDOVUDINE;

EID: 0035941538     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.285.4.402     Document Type: Short Survey

References (10)

1. Adverse effects associated with use of nevirapine in HIV postexposure for 2 health care workers
2. Severe hepatic failure related to nevirapine treatment
3. South Africa to tighten control on drug trials after five deaths
4. Update: Provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV
5. Public Health Service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis
6. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial
7. Public Health Service Task Force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States
8. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: Findings of the HIV Postexposure Prophylaxis Registry
9. Occupational risk of human immunodeficiency virus infection in healthcare workers: An overview
10. Incidence of rash and discontinuation of nevirapine using two different escalating initial doses